These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35355921)

  • 1. Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis.
    Dutta D; Surana V; Singla R; Aggarwal S; Sharma M
    Indian J Endocrinol Metab; 2021; 25(6):475-489. PubMed ID: 35355921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.
    Yu D; Shen S; Zhang J; Wang Q
    Clin Ther; 2023 Aug; 45(8):787-796. PubMed ID: 37455226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis.
    Caruso I; Di Gioia L; Di Molfetta S; Cignarelli A; Palmer SC; Natale P; Strippoli GFM; Perrini S; Natalicchio A; Laviola L; Giorgino F
    EClinicalMedicine; 2023 Oct; 64():102181. PubMed ID: 37719418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.
    Qin W; Yang J; Ni Y; Deng C; Ruan Q; Ruan J; Zhou P; Duan K
    Endocrine; 2024 Jun; ():. PubMed ID: 38850440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.
    Cai W; Zhang R; Yao Y; Wu Q; Zhang J
    Front Public Health; 2024; 12():1277113. PubMed ID: 38356942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.
    de Mesquita YLL; Pera Calvi I; Reis Marques I; Almeida Cruz S; Padrao EMH; Carvalho PEP; da Silva CHA; Cardoso R; Moura FA; Rafalskiy VV
    Int J Obes (Lond); 2023 Oct; 47(10):883-892. PubMed ID: 37460681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials.
    Bhagavathula AS; Vidyasagar K; Tesfaye W
    Pharmaceuticals (Basel); 2021 Sep; 14(10):. PubMed ID: 34681215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
    Bradley CL; McMillin SM; Hwang AY; Sherrill CH
    Ann Pharmacother; 2023 Jul; 57(7):822-836. PubMed ID: 36367094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.
    Tan B; Pan XH; Chew HSJ; Goh RSJ; Lin C; Anand VV; Lee ECZ; Chan KE; Kong G; Ong CEY; Chung HC; Young DY; Chan MY; Khoo CM; Mehta A; Muthiah MD; Noureddin M; Ng CH; Chew NWS; Chin YH
    Int J Obes (Lond); 2023 Aug; 47(8):677-685. PubMed ID: 37253796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of novel dual glucokinase activator dorzagliatin in type-2 diabetes A meta-analysis.
    Dutta D; Khandelwal D; Kumar M; Sharma M
    Diabetes Metab Syndr; 2023 Jan; 17(1):102695. PubMed ID: 36566614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Zhou Q; Lei X; Fu S; Liu P; Long C; Wang Y; Li Z; Xie Q; Chen Q
    Diabetol Metab Syndr; 2023 Oct; 15(1):222. PubMed ID: 37904255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Novel Dipeptidyl-Peptidase-4 Inhibitor Evogliptin in the Management of Type 2 Diabetes Mellitus: A Meta-Analysis.
    Dutta D; Bhattacharya S; Krishnamurthy A; Sharma LK; Sharma M
    Indian J Endocrinol Metab; 2020; 24(5):434-445. PubMed ID: 33489850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis.
    Ding Y; Shi Y; Guan R; Yan S; Liu H; Wang Z; Li J; Wang T; Cai W; Ma G
    Pharmacol Res; 2024 Jan; 199():107031. PubMed ID: 38061595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.
    Zaazouee MS; Hamdallah A; Helmy SK; Hasabo EA; Sayed AK; Gbreel MI; Elmegeed AA; Aladwan H; Elshanbary AA; Abdel-Aziz W; Elshahawy IM; Rabie S; Elkady S; Ali AS; Ragab KM; Nourelden AZ
    Diabetes Metab Syndr; 2022 Jun; 16(6):102511. PubMed ID: 35623229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis.
    Guan R; Yang Q; Yang X; Du W; Li X; Ma G
    Front Pharmacol; 2022; 13():998816. PubMed ID: 36313305
    [No Abstract]   [Full Text] [Related]  

  • 17. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.
    Min T; Bain SC
    Diabetes Ther; 2021 Jan; 12(1):143-157. PubMed ID: 33325008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management.
    Sinha R; Papamargaritis D; Sargeant JA; Davies MJ
    J Obes Metab Syndr; 2023 Mar; 32(1):25-45. PubMed ID: 36750526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3.
    Viljoen A; Pantalone KM; Galindo RJ; Cui X; Huh R; Hemmingway A; Fernández Landó L; Patel H
    Diabetes Ther; 2023 May; 14(5):925-936. PubMed ID: 37000390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis.
    Tang Y; Zhang L; Zeng Y; Wang X; Zhang M
    Front Pharmacol; 2022; 13():1016639. PubMed ID: 36569320
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.